[ad_1]
A roundup of the latest news and updates for patients with multiple myeloma from CURE®.
There have been several updates in the field of multiple myeloma over the last several weeks. Here, CURE® looks back at some of the latest news and updates in that space.
- Adding a first-of-its kind drug to a regimen for advanced multiple myeloma delayed the time until disease progression and reduced the rate of peripheral neuropathy, a side effect that causes numbness and tingling in the extremities.
- Patients with multiple myeloma now have the opportunity to contribute their health information to a database that will help doctors provide them with optimal care while aiding researchers in developing new treatments.
- The Food and Drug Administration (FDA) has issued an order to delay the phase 1 MELANI-01 trial, which is evaluating the CAR T-cell product UCARTCS1A in patients with relapsed or refractory multiple myeloma, according to a press release from the product’s manufacturer.
- Data from a study presented during the 2020 ASCO Virtual Scientific Program show that idecabtagene vicleucel (ide-cel), a novel CAR T-cell therapy which targets the B-cell maturation antigen (BCMA), demonstrated durable responses in patients with heavily pretreated relapsed/refractory multiple myeloma.
- The FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously voted in favor of the agency approving belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.
Get more news and updates on multiple myeloma here.
[ad_2]
